Navigation Links
Champions Oncology Reports Financial Results for the Year Ended April 30, 2012
Date:7/18/2012

or 38%.  The increase in costs was due to the increased volume of the TOS business.  Gross margin for TOS was 47% for the years ended April 30, 2012 and 2011.

POS revenues were $2.3 million and $3.4 million for the years ended April 30, 2012 and 2011, respectively, a decrease of $1.1 million, or 31%.  Panel revenue, a component of POS revenue, decreased $1.2 million from the prior year, which is primarily attributable to a decrease in pricing per panel.  Excluding panel revenue, POS revenue was $1.8 million and $1.7 million for the years ended April 30, 2012 and 2011, respectively, an increase of $0.1 million.  During fiscal 2012, the Company experienced significantly higher volumes of implants and drug studies compared to fiscal 2011.  For the year ended April 30, 2012, the Company performed 97 TumorGraft implants, compared to 12 in the prior year.  For the year ended April 30, 2012, the Company completed 19 drug studies, compared to 5 in the prior year.  The increase in volume was offset by decreased pricing for both the TumorGraft implants and drug studies, as part of our strategic decision to accelerate the growth of our Tumorbank.

Cost of POS was $2.4 million and $1.7 million for the years ended April 30, 2012 and 2011, respectively, an increase of $0.7 million, or 42%.  Gross margin for POS was -1% and 51% for the years ended April 30, 2012 and 2011, respectively.  Gross margins declined due to the strategic decision to decrease prices to drive increased volumes.  Additionally, during the second half of fiscal 2012, the Company transitioned its laboratory work in-house from a third-party CRO.  While this has resulted in increased costs during the transition, it is expected to yield future savings.  Finally, costs related to POS studies are expensed as incurred, so expenses include ongoing costs related to 11 drug studies in progress at April 30, 2012.

Research and developmen
'/>"/>

SOURCE Champions Oncology, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
2. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
3. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
4. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
5. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
6. Peer-reviewed Article Reports ProImmune's Immune Formulation 200® Activates the Immune-Support Gene Nrf2.
7. Prosperous Agriculture Reports Outstanding Sales Result for First Half of 2012
8. China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2012
9. GeneLink Reports First Quarter 2012 Financial Results
10. Genesis Biopharma Mentioned Favorably in BioMedReports Article
11. Vermillion Reports First Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014 Intarcia Therapeutics, Inc. ... from a study of the cost and predictability of ... th Annual Meeting of the European Association for ... today, Christian Frois , Ph.D., of Analysis Group, ... of planned Intarcia-sponsored, retrospective studies to characterize the prevalence ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - SQI Diagnostics Inc. ... develops and commercializes proprietary technologies and products for advanced ... been approved for trading in the United ... is expected to commence on September 17, 2014 on ... continue to trade on the TSX Venture Exchange under ...
(Date:9/17/2014)... de septiembre de 2014  Cryoport, Inc. ... mundial de soluciones logísticas avanzadas criogénicas para ... vida, anunció hoy la contratación de Broekman ... sede en Rótterdam, Países Bajos, para proporcionar ... en rápido crecimiento. Según los términos del ...
(Date:9/17/2014)... , September 17, 2014 ... of action from a truly novel class ... MGB Biopharma, a biopharmaceutical company developing ... today that it has secured £4.0m ($6.4m) ... antibacterial, MGB-BP-3, against a range of Gram-positive ...
Breaking Biology Technology:Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7
... Global Products, BASINGSTOKE, England, October 8 ... global specialty biopharmaceutical,company, announces that it has agreed ... Almirall for a cash consideration of $213m. The ... sodium),and VANIQA(R) (eflornithine hydrochloride), and six other non-promoted,products1 ...
... about the origins of quantum dot blinking, researchers ... Laboratory, the University of Chicago and the California ... characterize it on faster time scales than have ... also known as quantum dots, are being intensively ...
... to Vice President, Research Operations ... Non-Profit Foundation, CARLSBAD, Calif., Oct. 5 ... focused on the discovery and,development of small-molecule therapeutics ... diseases, today announced changes to its,research management. Dr. ...
Cached Biology Technology:Shire Divests Non-Core Product Portfolio to Almirall 2Shire Divests Non-Core Product Portfolio to Almirall 3Argonne researcher studies what makes quantum dots blink 2Ardea Biosciences Announces Changes to Research Management 2Ardea Biosciences Announces Changes to Research Management 3
(Date:9/15/2014)... from digestion to disease resistance. Despite the fact that ... the planet, more is known about belly-button bacteria than ... colleagues working on Panama,s Barro Colorado Island discovered that ... to more than 400 different kinds of bacteria. The ... 7,000 different kinds. , Bacteria in tropical forests may ...
(Date:9/15/2014)... that lowland tapir populations may continue to drop in ... from the Office National de la Chasse et de ... Zoo Global reviewed data retrieved from camera traps in ... and compared this data to current harvest rates in ... tapirs in French Guiana," said Matthias Tobler, a scientist ...
(Date:9/15/2014)... a morphine regimen can result in better pain control ... the dosage of the opioid needed to be effective, ... University. , The result could bring significant relief to ... felt in the arms and legs and associated with ... need for better treatments for neuropathic pain," said Fletcher ...
Breaking Biology News(10 mins):Smithsonian scientists discover tropical tree microbiome in Panama 2IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2
... University of Delaware have developed a "smart" hydrogel that can ... Over the past few decades, smart hydrogels have been created ... "The idea of a smart hydrogel that can release ... professor of materials science and engineering and biomedical engineering. "What,s ...
... Living organisms have adapted to the day-night cycle and, in ... are not completely known yet but its functioning has been ... of normal circadian rhythms can have deleterious effects on health; ... the time of feeding was shown to affect the ability ...
... of the white-throated sparrow has identified a biological pathway connecting ... wild to variation in their genome. The Proceedings ... is publishing the results of the experiments, conducted by the ... Psychology. The research, which comprised behavioral observations ...
Cached Biology News:UD-developed smart gels deliver medicine on demand 2The internal clock and feeding rhythm set the pace of the liver 2Wild sparrow study traces social behaviors in the field to specific gene 2Wild sparrow study traces social behaviors in the field to specific gene 3Wild sparrow study traces social behaviors in the field to specific gene 4
... Anti-Natural Killer Cell Receptor-P1, ... Immunogen: Hybridoma produced ... from BALB/c mice immunized (BALB/c ... (LAK) cells and mouse myeloma ...
... Yersinia pestis This antibody is ... Immunogen: Purified F1 ... vaccine strain EV76. Specificity: ... capsular antigen. There is no cross-reactivity ...
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
Anti-human C3a/C3a des-Arg (neo-epitope), Clone 2991, Monoclonal Antibody...
Biology Products: